Zacks12d agobearish
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss EstimatesCRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.
Notícias
Apenas manchetes de alto sinal — eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
48last 24h
1672last 7d
313🟢 bullish (7d)
171🔴 bearish (7d)
136publishers